United States· US:50419-346_4314fa34-edbc-44f3-b40b-277c6fbd2ab0
Ultravist
A iopromide product containing iopromide, registered in United States by Bayer HealthCare Pharmaceuticals Inc.. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Iopromide is registered in 13 of 19 countries.
Countries holding a registration under ATC V08AB05 (iopromide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Iopromide · ATC V08AB05
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- IOPROMIDE
- Manufacturer
- Bayer HealthCare Pharmaceuticals Inc.
- Country
- United States (US)
- ATC code
- V08AB05
- ATC class
- Iopromide
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 20
- ndc11504193460510 VIAL, GLASS in 1 CARTON (50419-346-05) / 50 mL in 1 VIAL, GLASS
- ndc11504193461010 VIAL, GLASS in 1 CARTON (50419-346-10) / 100 mL in 1 VIAL, GLASS
- ndc11504193461510 VIAL, GLASS in 1 CARTON (50419-346-15) / 150 mL in 1 VIAL, GLASS
- ndc11504193462010 VIAL, GLASS in 1 CARTON (50419-346-20) / 200 mL in 1 VIAL, GLASS
- ndc11504193462610 BOTTLE in 1 PACKAGE (50419-346-26) / 200 mL in 1 BOTTLE (50419-346-32)
- ndc11504193462810 BOTTLE in 1 PACKAGE (50419-346-28) / 200 mL in 1 BOTTLE
- ndc1150419346588 BOTTLE in 1 PACKAGE (50419-346-58) / 500 mL in 1 BOTTLE (50419-346-33)
- ndc1150419346658 BOTTLE in 1 PACKAGE (50419-346-65) / 500 mL in 1 BOTTLE
- ndc11504193469110 VIAL, GLASS in 1 CARTON (50419-346-91) / 100 mL in 1 VIAL, GLASS
- ndc1150419346978 BOTTLE in 1 PACKAGE (50419-346-97) / 500 mL in 1 BOTTLE
- ndc1150419-346-05
- ndc1150419-346-10
- ndc1150419-346-15
- ndc1150419-346-20
- ndc1150419-346-26
- ndc1150419-346-28
- ndc1150419-346-58
- ndc1150419-346-65
- ndc1150419-346-91
- ndc1150419-346-97
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
232 interactions on record for iopromide.
Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Iopromide · interactions on record
232 records
- 94 severe
- 55 moderate
- 83 info
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Iopromide in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaULTRAVISTBayer AG, Leverkusen
- BelgiumUltravist 240 240 mg/mlBayer
- Japanイオプロミドバイエル薬品
- United KingdomUltravist 150 solution for injection 50ml vialsBayer Plc
- GermanyUltravist 300Eurocontrast Gmbh
- FranceULTRAVIST 300 (300 mg d'Iode/mL), solution injectableBAYER HEALTHCARE
- SwedenUltravist 150 mg I/ml Injektions-/infusionsvätska, lösningBayer AB
- SpainULTRAVIST 240 mg /ml, SOLUCION INYECTABLE Y PARA PERFUSION EN VIALBayer Hispania S.L.
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Ultravist
- Belgium · Ultravist
- Bulgaria · Ултравист
- Cyprus · Ultravist 300, Ultravist 370
- Czechia · Ultravist
- Germany · Ultravist 300, Ultravist-240
- Denmark · Ultravist
- Estonia · Ultravist
- Spain · Ultravist
- France · Ultravist
- Greece · Ultravist
- Croatia · Ultravist
- Hungary · Ultravist
- Italy · Ultravist
- Lithuania · Ultravist
- Luxembourg · Ultravist
- Latvia · Ultravist
- Malta · Ultravist 370
- Netherlands · Ultravist
- Norway · Ultravist
- Poland · Ultravist 300, Ultravist 370
- Portugal · Ultravist 240, Ultravist 300
- Romania · Ultravist
- Sweden · Ultravist
- Slovenia · Ultravist
- Slovakia · Ultravist
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/303695d4-c841-45cc-9201-6384abfdcf06 GET /v1/drugs/303695d4-c841-45cc-9201-6384abfdcf06?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRA-ARTERIAL; INTRAVENOUS",
"source": "ndc",
"strength": "370",
"substance": "IOPROMIDE",
"productndc": "50419-346",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "NDA020220",
"marketing_category": "NDA"
}See everything about iopromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.